Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization

American Journal of Pathology

Volumn 149, Issue 5, 1996, Pages 1575-1584

  Kobayashi, Masako ^a   Kawashima, Atsuhiro ^a   Mai, Masayoshi ^a   Ooi, Akishi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CHROMOSOME 17P; CHROMOSOME DELETION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA;

CARCINOMA; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 17; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0029855316     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM: Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986, 320:84-85
2. Hansen MF, Cavenee WK: Genetics of cancer predisposition. Cancer Res 1987, 47:5518-5527
3. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN: Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 1993, 53:2614-2617
4. Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR, Shibata D: p53 mutations and microsatellite instability in sporadic gastric cancer when guardians fail. Cancer Res 1994, 54:4750-4755
5. Poremba C, Yandell DW, Huang Q, Little JB, Mellin W, Schmid KW, Böcker W, Dockhorn-Dworniczak B: Frequency and spectrum of p53 mutations in gastric cancer: a molecular genetic and immunohistochemical study. Virchows Arch 1995, 426:447-455
6. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S: p53 mutation in gastric cancer a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 1993, 54:759-764
7. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: p53 alteration in gastric precancerous lesions. Am J Pathol 1994, 144:511-517
8. Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, Yasui W, Ito H, Tahara E: p53 mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol 1992, 119:67-70
9. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S: Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res 1991, 51:3056-3058
10. Matozaki T, Sakamoto C, Suzuki T, Matsuda K, Uchida T, Nakano O, Wada K, Nishisaki H, Konda Y, Nagao M, Kasuga M: p53 gene mutation in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res 1992, 52:4335-4341
11. Wada M, Yokota J, Mizoguchi H, Sugimura T, Terada M: Infrequent loss of chromosomal heterozygosity in human stomach cancer. Cancer Res 1988, 48:2988-2992
12. Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H, Nakamura Y, Kajiyama G, Tahara E: Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p on human gastric carcinomas. Cancer Res 1991, 51:2926-2931
13. Fey MF, Hesketh C, Wainscoat JS, Gendler S, Thein SL: Clonal allelic loss in gastrointestinal cancers. Br J Cancer 1989, 59:750-754
14. Matsumura K, Kallioniemi A, Kallioniemi O, Chen L, Smith HS, Pinkel D, Gray J, Waldman FM: Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res 1992, 52:3474-3477
15. Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ, Waldman FM: Physical deletion of the p53 gene in bladder cancer: detection by fluorescence in situ hybridization. Am J Pathol 1994, 144:756-766
16. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: histological implications. Acta Pathol Microbiol Scand 1965, 64:31-49
17. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM: Analysis of p53 expression in human tumors: an antibody raised against human p53 expressed in Esherichia coli. J Cell Sci 1992, 101:183-189
18. Nakanishi Y, Noguchi M, Matsuno Y, Mukai K, Simosoto Y, Hirohashi S: p53 expression in squamous cell carcinoma and dysplasia of vocal cords and oral cavity. Appl Immunohistochem 1993, 1:101-107
19. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29:577-580
20. Nakamura Y, Ballard L, Leppert M, Connell PO, Lathrop GM, Lalouel JM, White R: Isolation and mapping of a polysomic DNA sequence (pYNZ22) on chromosome 17p [D17S30]. Nucleic Acids Res 1988, 16:5707
21. Oda Y, Tanaka M, Nakanishi I: Relation between the occurrence of K-ras gene point mutations and genotypes of polymorphic N-acetyltransferase in human colorectal carcinomas. Carcinogenesis 1994, 15: 1365-1369
22. Hopman AHN, Ramaekers FCS, Raap AK, Beck JLM, Devilee P, van der Ploeg M, Vooijs GP: In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 1988, 89:307-316
23. Waldman FM, Carroll PR, Kerschmann R, Cohen MB, Field FG, Mayall BH: Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res 1991, 51:3807-3813
24. Soussi T, Fromentel CC, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990, 5:945-952
25. Bosari S, Viale G: The clinical significance of p53 aberrations in human tumors. Virchows Arch 1995, 427: 229-241
26. Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J 1990, 9:1595-1602
27. Tohdo H, Yokozaki H, Haruma K, Kajiyama G, Tahara E: p53 gene mutation in gastric adenomas Virchows Arch B Cell Pathol 1993, 63:191-195
28. Milner J, Medcalf EA: Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991, 65:765-774
29. Ranzani GN, Renault B, Pellegata NS, Fattorini, Magni E, Bacci F, Amadori D: Loss of heterozygosity and K-ras gene mutations in gastric cancer. Hum Genet 1993, 92:244-249
30. Delattre O, Olschwang S, Law DJ, Merot T, Remvicos Y, Salomon RJ, Sastre X, Validire P, Feinberg AP, Thomas G: Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989, 12:353-356
31. Lane DP: p53, guardian of the genome. Nature 1992, 358:15-16
32. Mercer WE, Shields MT, Lin D, Appella E, Ullrich SJ: Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 1991, 1962, 88:1958
33. Chen LC, Nuebauer A, Kurisu W, Waldman FM, Ljung BM, Goodson W III, Goldman ES, Moorell D, Balazs M, Liu E, Mayall BH, Smith HS: Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneupoidy in primary human breast cancer. Proc Natl Acad Sci USA 1991, 88:3847-3851
34. Kitayama Y, Sugimura H, Tanaka M, Nakamura S, Kino I: Expression of p53 and flow cytometric DNA analysis of isolated neoplastic glands of the stomach: an application of the gland isolation method. Virchows Arch 1995, 426:557-562
35. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S: High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992, 83:978-984
36. Wagner RP: Mitotic recombination is generally rare but has key effects and some differing mechanisms. Chromosomes. Edited by RP Wagner, MP Maguire, RL Stallongs. New York, Wiley-Liss, 1993, pp 176-178